HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with tuberculous meningitis.

Abstract
As inflammatory changes play an important role in the neuropathogenesis of the disease, adjunctive corticosteroid treatment may be of benefit in tuberculous meningitis. In an open-label study in India, 97 patients with such meningitis were randomized into a control group, a dexamethasone group (with the drug given intravenously once a day for 4 weeks, and then orally, once daily, for another 4 weeks) and a methylprednisolone group (with the drug given intravenously once a day for 5 days). All the patients also received standard anti-tuberculosis drugs. The primary outcome measure was death or severe disability 6 months after the randomization, with a modified Rankin scale used to assess each patient's level of disability. The other outcome measures investigated were deterioration in vision, focal neurological deficits and new-onset seizures. Six patients (one of those given dexamethasone, three of those given methylprednisolone and two of those in the control group) were lost to follow-up. Although each corticosteroid was associated with a reduction in death or disability, this reduction did not reach statistical significance in either the dexamethasone group (relative risk of death=0.6, with a 95% confidence interval of 0.29-1.2; P>0.05) or the methylprednisolone group (relative risk of death=0.7, with a 95% confidence interval of 0.4-1.4; P>0.05), probably because of the small sample sizes. Among the patients who died within 10 months of randomization, the mean time to death (post-randomization) was 8.8 months in the dexamethasone group, 8.2 months in the methylprednisolone group, and 7.1 months in the control group (P>0.05). The prevalence of impaired vision, among all the patients evaluated, decreased from 41.8% at baseline to 29.9% (among the survivors) 6 months later. Adverse events were similar and equally reported in the two corticosteroid groups. Larger trials are still needed to determine if dexamethasone and/or methylprednisolone are useful in the treatment of tuberculous meningitis, at least in India.
AuthorsH S Malhotra, R K Garg, M K Singh, A Agarwal, R Verma
JournalAnnals of tropical medicine and parasitology (Ann Trop Med Parasitol) Vol. 103 Issue 7 Pg. 625-34 (Oct 2009) ISSN: 1364-8594 [Electronic] England
PMID19825284 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Anti-Inflammatory Agents
  • Dexamethasone
  • Methylprednisolone
Topics
  • Adolescent
  • Adult
  • Aged
  • Anti-Inflammatory Agents (administration & dosage)
  • Chemotherapy, Adjuvant
  • Confidence Intervals
  • Dexamethasone (administration & dosage)
  • Drug Administration Schedule
  • Female
  • Humans
  • India (epidemiology)
  • Injections, Intravenous
  • Male
  • Methylprednisolone (administration & dosage)
  • Middle Aged
  • Pilot Projects
  • Prospective Studies
  • Treatment Outcome
  • Tuberculosis, Meningeal (cerebrospinal fluid, drug therapy, mortality)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: